Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences

Next Previous
X
Search
Drug Profile

Regadenoson - Astellas Pharma/Rapidscan Pharma Solutions/Gilead Sciences

Alternative Names: CVT 3146; Lexiscan; Rapiscan

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CV Therapeutics
  • Developer Astellas Pharma; GE Healthcare; Gilead Sciences; National Jewish Health; Rapidscan Pharma Solutions
  • Class Imaging agents; Purines; Pyrazoles; Small molecules; Vasodilators
  • Mechanism of Action Adenosine A2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders
  • No development reported Pulmonary hypertension

Most Recent Events

  • 30 Dec 2022 The Court of Appeals for the Federal Circuit affirms the decision of the U.S. District Court for the District of Delaware regarding patent infringement related to regadenoson injection by Hospira
  • 20 May 2022 Astellas Pharma confirms unfavorable district court decision in regadenoson patent trial
  • 15 Feb 2022 The EMA approves regadenoson for stress cardiac magnetic resonance imaging for Coronary disorders (Diagnosis) in European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top